Alirocumab

證據等級: L5

預測適應症: 10 個

Alirocumab: From Hypercholesterolaemia to Cholesterol Catabolic Process Disease

One-Sentence Summary

Alirocumab (Praluent) is a fully human anti-PCSK9 monoclonal antibody originally approved in major markets for the treatment of hypercholesterolaemia and reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (ASCVD). Among 10 TxGNN-predicted indications, Cholesterol Catabolic Process Disease — a broad category encompassing disorders of impaired LDL clearance such as familial hypercholesterolaemia and HIV-associated dyslipidaemia — emerges as the most actionable candidate, with 1 completed Phase 3 clinical trial and 19 publications currently supporting this direction. This is the only prediction in this pack to reach an actionable evidence level; the remaining 9 predictions are assessed as Hold due to absent biological plausibility or zero supporting evidence.

Quick Overview

Item	Content
Original Indication	Hypercholesterolaemia / Cardiovascular risk reduction (established ASCVD)
Predicted New Indication	Cholesterol Catabolic Process Disease
TxGNN Prediction Score	99.36%
Evidence Level	L2
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Alirocumab is a fully human IgG1κ monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9), a serine protease secreted primarily by the liver. Circulating PCSK9 normally binds to the LDL receptor (LDLR) on hepatocyte surfaces and directs it toward lysosomal degradation, reducing the cell's capacity to clear LDL particles from the bloodstream. Alirocumab complexes with free PCSK9 in plasma, preventing this interaction. The result is a 2–4-fold increase in hepatic LDLR surface density and a sustained reduction in plasma LDL-C of 40–60%, as demonstrated across the ODYSSEY clinical programme (>47,000 patient-years in ODYSSEY OUTCOMES).

"Cholesterol catabolic process disease" as a broad disease category captures any condition in which LDL clearance is pathologically impaired — whether due to primary genetic defects (familial hypercholesterolaemia caused by gain-of-function PCSK9 mutations or loss-of-function LDLR/ApoB mutations), or secondary causes such as HIV antiretroviral therapy-associated dyslipidaemia or metabolic syndrome. In all of these conditions, the shared molecular bottleneck is inadequate LDLR-mediated hepatic LDL uptake — precisely the step that PCSK9 inhibition restores. This mechanistic alignment makes the TxGNN prediction biologically coherent, not merely a topological coincidence in the knowledge graph.

The completed Phase 3 trial NCT03207945 (EPIC-HIV Study) directly illustrates this extension: HIV-infected individuals on antiretroviral therapy develop a distinctive pattern of impaired cholesterol catabolism accompanied by increased vascular inflammation and non-calcified plaque burden. This trial evaluated whether PCSK9 inhibition could reverse these changes, representing a real-world repurposing of alirocumab into a cholesterol catabolic disease population that extends beyond its original cardiovascular indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03207945	Phase 3	Completed	118	EPIC-HIV Study: evaluated PCSK9 inhibition with alirocumab in ART-treated HIV-infected adults; primary endpoints included vascular inflammation (FDG-PET/CT), endothelial function, and non-calcified coronary plaque volume — all hallmarks of HIV-associated cholesterol catabolic dysfunction. HIV-related atherosclerosis features a predominance of non-calcified plaque distinct from the general population, making this a biologically distinct repurposing context.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36411665	2022	Systematic Review / Safety Analysis	Biomedicine & Pharmacotherapy	Comprehensive safety analysis of PCSK9 inhibitors demonstrating favourable tolerability; establishes the clinical gap — >43% of statin-treated patients fail LDL-C targets — that PCSK9 inhibition fills in cholesterol catabolic disorders
36739653	2023	Systematic Review / Meta-analysis	Kardiologia Polska	Reviews biochemical and genomic evidence for PCSK9's role in LDL metabolism; meta-analyses show consistent LDL-C reduction and cardiovascular event reduction across large Phase 3 trials
37686091	2023	Narrative Review	Int J Molecular Sciences	Comprehensive review of dyslipidaemia treatment, positioning PCSK9 inhibitors as a key intervention for patients with cholesterol metabolic disorders inadequately managed by statins
38277255	2024	Narrative Review	Current Opinion in Lipidology	Update on PCSK9-directed therapies including novel strategies in development; contextualises alirocumab within the broader landscape of cholesterol catabolism modulation
38658193	2024	Large-Scale Safety Analysis	Eur Heart J Cardiovascular Pharmacotherapy	ODYSSEY OUTCOMES data (>47,296 patient-years): alirocumab reduces recurrent ischaemic events and all-cause mortality with no unexpected long-term safety signals — the most comprehensive alirocumab safety dataset available
38185721	2024	Translational Review	Signal Transduction & Targeted Therapy	Extends PCSK9 biology to liver disease, infectious diseases, and autoimmune disorders; highlights pleiotropic roles relevant to secondary cholesterol catabolic diseases
39947256	2025	Mechanistic Review	Pharmacology & Therapeutics	Compares extracellular (alirocumab/evolocumab) vs intracellular (inclisiran) PCSK9 targeting; clarifies mechanism-of-action nuances critical for patient selection in cholesterol catabolic disorders
39751968	2025	Review	Current Atherosclerosis Reports	Novel pharmacological therapies for homozygous familial hypercholesterolaemia (HoFH) — the most severe hereditary form of impaired cholesterol catabolism; reviews emerging role of PCSK9 inhibitors in this population
34070931	2021	Mechanistic Review	Int J Molecular Sciences	Foundational review of PCSK9 biology and its role in atherothrombosis; establishes the mechanistic basis for LDL clearance restoration via PCSK9 inhibition
39679827	2025	State-of-the-Art Review	Pharmacotherapy	Current and emerging PCSK9-directed therapies for LDL-C reduction and ASCVD risk; integrates evidence from ODYSSEY, FOURIER, and emerging PCSK9 modalities

Singapore Market Information

Alirocumab is currently not registered with the Health Sciences Authority (HSA) of Singapore. No marketing authorisations, product licences, or historical registrations have been identified in the HSA database.

For reference: Alirocumab (Praluent®) holds regulatory approval in the United States (FDA; 2015), the European Union (EMA; 2015), Japan (PMDA), and other major jurisdictions for hypercholesterolaemia and cardiovascular risk reduction. A Singapore market entry would require a formal HSA New Drug Application supported by pivotal trial data and, where applicable, bridging data for the local population.

Safety Considerations

Please refer to the package insert for safety information.

Note from available evidence: The ODYSSEY OUTCOMES trial (PMID 38658193) provides the largest safety dataset for alirocumab (>47,296 patient-years of placebo-controlled observation). Key known adverse effects include injection-site reactions and nasopharyngitis; no unexpected long-term safety signals were identified. Formal warning and contraindication data from a regulatory package insert were not available for this analysis (Data Gap: Blocking — see DG001).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alirocumab's core mechanism — PCSK9 inhibition restoring hepatic LDL receptor function — is directly and specifically aligned with the pathophysiology of cholesterol catabolic process diseases. One completed Phase 3 trial in HIV-associated dyslipidaemia (a prototypical secondary cholesterol catabolic disorder) combined with 19 high-quality publications including the ODYSSEY OUTCOMES safety dataset constitutes L2 evidence strength, sufficient to advance beyond a pure research question into structured clinical development planning.

To proceed, the following is needed:

Resolve Blocking Data Gap (DG001): Obtain the HSA or FDA/EMA package insert to extract formal contraindications and boxed warnings before any clinical safety review can be completed
Resolve High Data Gap (DG002): Retrieve MOA documentation from DrugBank API to formalise mechanistic rationale for regulatory submissions
Define target sub-population: Narrow "cholesterol catabolic process disease" to a specific actionable sub-indication (e.g., HIV-associated dyslipidaemia in ART-treated patients, statin-intolerant heterozygous FH, or post-ACS residual LDL risk) to focus development resources
Obtain and review EPIC-HIV (NCT03207945) full publication: Confirm primary and secondary imaging endpoint results before proposing any label extension strategy
Singapore registration pathway assessment: Engage HSA to determine whether a full NDA, abridged application, or mutual recognition pathway is appropriate given existing US/EU approvals
Discard 9 remaining TxGNN predictions: All other predicted indications in this pack are assessed as Hold — either due to mechanistic contraindication (DHT backdoor pathway defect, cholesterol synthesis defect), absence of any biological plausibility (dappled diaphyseal dysplasia, HADH deficiency), or pure KG topological noise (X-linked ichthyosis, vitamin/cofactor disorders, NLSD, SPOAN)

This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.